Dr. Ryan C. Martin, M.D.
Heart Failure & Transplant Cardiology (Advanced Heart Failure and Transplant Cardiology Physician)
- Medicare participating
At a glance
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 626
Licensed in Washington since 2016, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Advanced Heart Failure and Transplant Cardiology Physician primary
CO license DR.0070737 (first issued 2023; active) · GA license 82851 · WA license MD60636162 (first issued 2016; expired) -
Cardiovascular Disease Physician
WA license MD60636162 (first issued 2016; expired) -
Internal Medicine Physician
GA license 80443
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Heart Failure & Transplant Cardiology per capita by county →
Where they work
Hospitals
- University of Colorado Hospital Authority Aurora, CO
- Denver Health & Hospital Authority Denver, CO
Medical groups
- Denver Health and Hospital Authority (849 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 626
- Services billed
- 961
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 173 | 45 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 160 | 115 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 157 | 149 |
| Evaluation of lower heart chamber assist device | 120 | 33 |
| Established patient office or other outpatient visit, 30-39 minutes | 62 | 51 |
| Insertion of needle into vein for collection of blood sample | 41 | 26 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 40 | 33 |
| Critical care, first 30-74 minutes | 28 | 11 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 26 | 14 |
| Established patient office or other outpatient visit, 40-54 minutes | 21 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $137 in total to this clinician.
| Abbott Laboratories | $137 |
|---|
| Food and Beverage | $137 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $68,124 in research payments for these studies, mostly to the institutions running them.
- REDEFINE-HF Study #22438
Bayer HealthCare Pharmaceuticals Inc. - Confirmation Study #22563
Bayer HealthCare Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.